Study to Characterize the Pharmacokinetics of Raltegravir in the Gastrointestinal (GI) Tract of Healthy Male Volunteers
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the way the first commercially available
integrase inhibitor, raltegravir, a new class of antiretrovirals that is used to treat HIV,
is distributed into the rectal mucosal tissue. This information will generate important
information regarding the drug's penetration into lymphoid tissues that are rapidly depleted
in HIV infection. Subsequently strategies to prevent the sexual transmission of HIV and for
treating HIV-infected individuals will be designed.